These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
110 related items for PubMed ID: 11487715
1. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. Malingré MM, Ten Bokkel Huinink WW, Duchin K, Schellens JH, Beijnen JH. Anticancer Drugs; 2001 Aug; 12(7):591-3. PubMed ID: 11487715 [Abstract] [Full Text] [Related]
2. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH. Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431 [Abstract] [Full Text] [Related]
3. Phase I and pharmacokinetic study of oral paclitaxel. Malingré MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, Schellens JH. J Clin Oncol; 2000 Jun 16; 18(12):2468-75. PubMed ID: 10856107 [Abstract] [Full Text] [Related]
4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH. Clin Cancer Res; 1999 Nov 16; 5(11):3379-84. PubMed ID: 10589748 [Abstract] [Full Text] [Related]
5. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JH. Cancer Chemother Pharmacol; 2001 Apr 16; 47(4):347-54. PubMed ID: 11345652 [Abstract] [Full Text] [Related]
6. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Malingré MM, Ten Bokkel Huinink WW, Mackay M, Schellens JH, Beijnen JH. Eur J Clin Pharmacol; 2001 Jul 16; 57(4):305-7. PubMed ID: 11549208 [Abstract] [Full Text] [Related]
7. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH. Cancer Chemother Pharmacol; 2007 Jan 16; 59(1):43-50. PubMed ID: 16680462 [Abstract] [Full Text] [Related]
8. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A. Anticancer Drugs; 2008 Mar 16; 19(3):275-81. PubMed ID: 18510173 [Abstract] [Full Text] [Related]
9. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JH. Anticancer Drugs; 2001 Apr 16; 12(4):351-8. PubMed ID: 11335792 [Abstract] [Full Text] [Related]
10. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Malingré MM, Schellens JH, van Tellingen O, Rosing H, Koopman FJ, Duchin K, Huinink WW, Swart M, Beijnen JH. Anticancer Drugs; 2000 Nov 16; 11(10):813-20. PubMed ID: 11142688 [Abstract] [Full Text] [Related]
11. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathôt RA, Rosing H, Schot ME, Van Tinteren H, Schellens JH. Ann Oncol; 2003 Feb 16; 14(2):197-204. PubMed ID: 12562644 [Abstract] [Full Text] [Related]
12. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH. Br J Cancer; 2001 Jan 05; 84(1):42-7. PubMed ID: 11139311 [Abstract] [Full Text] [Related]
15. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH. Br J Cancer; 2006 Sep 18; 95(6):729-34. PubMed ID: 16926835 [Abstract] [Full Text] [Related]
16. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Yang S, Gursoy RN, Lambert G, Benita S. Pharm Res; 2004 Feb 18; 21(2):261-70. PubMed ID: 15032307 [Abstract] [Full Text] [Related]
17. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA. Bone Marrow Transplant; 2000 Sep 18; 26(5):545-51. PubMed ID: 11019845 [Abstract] [Full Text] [Related]
18. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Clin Cancer Res; 1998 Oct 18; 4(10):2293-7. PubMed ID: 9796957 [Abstract] [Full Text] [Related]
19. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Schädeli F, Marti HP, Frey FJ, Uehlinger DE. Clin Pharmacokinet; 2002 Oct 18; 41(1):59-69. PubMed ID: 11825097 [Abstract] [Full Text] [Related]
20. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathôt RA, Marcus S, van Tinteren H, Baas P. J Clin Oncol; 2002 Dec 01; 20(23):4508-16. PubMed ID: 12454106 [Abstract] [Full Text] [Related] Page: [Next] [New Search]